Vitamin D3 (Cholecalciferol)
The fat-soluble vitamin that behaves like a hormone. Large trials (VITAL, DO-HEALTH, D-Health) reframed it: routine high-dose supplementation does not cut cardiovascular events or all-cause mortality in already-replete people, but correcting a genuine deficiency remains one of the highest-value, lowest-cost interventions in the longevity toolkit.
Reviewed & fact-checked by
BiohackingHub Research TeamEditorial Research Team · Last updated: July 24, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is Vitamin D3?
Vitamin D3 (cholecalciferol) is the form of vitamin D your skin makes from sunlight and the form used in most supplements. It is technically not a vitamin at all but a prohormone: the body converts it to 25-hydroxyvitamin D — the circulating form measured on blood tests — and then to the active hormone 1,25-dihydroxyvitamin D, which binds a nuclear receptor expressed in nearly every tissue.
That receptor's reach is why vitamin D gets linked to almost everything. It is also why the honest story is more measured than the supplement aisle suggests.
What the Big Trials Actually Showed
Three large randomised trials reset expectations:
- VITAL (25,871 adults, 2000 IU/day) found no reduction in cardiovascular events or invasive cancer over ~5 years in a largely vitamin-D-replete population.
- DO-HEALTH (2157 older Europeans) found no benefit of 2000 IU/day on a composite of blood pressure, infection, falls, fractures, and cognition.
- The D-Health Trial (21,315 adults, 60,000 IU/month) found no reduction in all-cause mortality.
The takeaway is not "vitamin D is useless." It is that supplementing people who are already replete does little — the benefit lives in correcting genuine deficiency, and the large trials mostly enrolled people who weren't deficient. VITAL's own follow-up did show fewer fractures only in specific analyses, and a BMJ meta-analysis found a modest reduction in acute respiratory infections concentrated in the most deficient participants.
Target Blood Level, Not a Fixed Dose
The single most useful shift is to dose to a blood level, not a number of pills. Aim for a 25(OH)D of roughly 30–50 ng/mL (75–125 nmol/L). For most adults not getting midday sun, 2000–4000 IU/day reaches that range; deficient individuals may need more short-term, and body weight matters (larger people need more). Retest after 8–12 weeks.
Use D3, not D2 — a meta-analysis found cholecalciferol raises and sustains 25(OH)D more effectively than ergocalciferol.
Dosage
| Parameter | Recommendation |
|---|---|
| Low | 1000 IU (25 mcg)/day |
| Typical | 2000–4000 IU (50–100 mcg)/day |
| Target level | 25(OH)D 30–50 ng/mL |
| Form | D3 (cholecalciferol), with a fatty meal |
| Cofactors | Vitamin K2, magnesium, boron |
The Cofactor Point
Vitamin D does not work alone. Magnesium is required for every step that activates it — supplementing D3 while magnesium-deficient blunts the response. And because D3 increases calcium absorption, vitamin K2 matters for where that calcium ends up: bone, not arterial wall. This is the logic of the Bone & Arterial Longevity protocol.
Safety
Vitamin D3 has a wide safety margin. Toxicity is real but requires sustained very high intake — hypercalcaemia is typically seen only above ~10,000 IU/day for months, and a 2023 systematic review found 3200–4000 IU/day well tolerated without excess adverse events. The people who should be cautious are those with sarcoidosis, primary hyperparathyroidism, or a history of calcium-based kidney stones. More is not better once you are replete.
Related Research
Stacking Interactions
How Vitamin D3 (Cholecalciferol) interacts with other compounds
Protocols using Vitamin D3 (Cholecalciferol)
Evidence-graded stacks that include this compound
Safety Profile — Tier A
Well-tolerated — strong human evidence
Contraindications
- ●Hypercalcaemia or hypercalciuria
- ●Sarcoidosis and other granulomatous disease (dysregulated activation)
- ●Primary hyperparathyroidism
- ●Some thiazide diuretic users (calcium retention)
Side Effects
- ●None at physiological doses (≤4000 IU/day)
- ●Hypercalcaemia only with sustained very high intake (typically >10,000 IU/day for months)
- ●Nausea, kidney stones, and soft-tissue calcification are toxicity signs, not routine effects